Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. (Q35675435)
Jump to navigation
Jump to search
scientific article published on 10 September 2014
Language | Label | Description | Also known as |
---|---|---|---|
English | Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors. |
scientific article published on 10 September 2014 |
Statements
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors (English)
Mark T Madsen
Thomas O'cdorisio
Saima Muzahir
10 September 2014
10 September 2014
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference